您当前所在的位置:首页 > 产品中心 > 产品详细信息
81403-80-7 分子结构
点击图片或这里关闭

N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide

ChemBase编号:230
分子式:C19H27N5O4
平均质量:389.44878
单一同位素质量:389.20630437
SMILES和InChIs

SMILES:
O1C(CCC1)C(=O)NCCCN(c1nc2c(c(n1)N)cc(OC)c(OC)c2)C
Canonical SMILES:
COc1cc2nc(nc(c2cc1OC)N)N(CCCNC(=O)C1CCCO1)C
InChI:
InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
InChIKey:
WNMJYKCGWZFFKR-UHFFFAOYSA-N

引用这个纪录

CBID:230 http://www.chembase.cn/molecule-230.html

Collapse All Expand All

名称和登记号

名称和登记号

名称 登记号
IUPAC标准名
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
IUPAC传统名
alfuzosin
N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}oxolane-2-carboxamide
商标名
Uroxatral
Xatral
别名
Alfusosine
alfuzosin
Alfuzosin
Zatral
Alfoten
Mittoral
Urion
Alfuzosin
CAS号
81403-80-7
PubChem SID
160963693
46508512
PubChem CID
2092

数据来源

数据来源

所有数据来源 商品来源 非商品来源
数据来源 数据ID 价格
InterBioScreen
Bio-0003 external link 加入购物车 请登录

理论计算性质

理论计算性质

JChem ALOGPS 2.1
Acid pKa 14.639695  质子受体
质子供体 LogD (pH = 5.5) -0.34812674 
LogD (pH = 7.4) 0.936928  Log P 1.1875362 
摩尔折射率 107.1141 cm3 极化性 41.11549 Å3
极化表面积 111.83 Å2 可自由旋转的化学键
里宾斯基五规则 true 
Log P 2.02  LOG S -3.14 
溶解度 2.82e-01 g/l 

分子性质

分子性质

理化性质 药理学性质 产品相关信息 生物活性(PubChem)
疏水性(logP)
1.4 expand 查看数据来源
生物活性机理
alpha 1-Adrenoceptor antagonist expand 查看数据来源
应用领域
Antihypertensive agent expand 查看数据来源
Used in the treatment of benign prostatic hypertrophy expand 查看数据来源

详细说明

详细说明

DrugBank DrugBank
DrugBank -  DB00346 external link
Item Information
Drug Groups approved; investigational
Description Alfuzosin (INN, provided as the hydrochloride salt) is an alpha-adrenergic blocker used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. [Wikipedia]
Indication For the reduction of urinary obstruction and relief of associated manifestations (eg. sensation of incomplete bladder emptying or straining, urgency, interrupted or weak stream) in patients with symptomatic beningn prostatic hyperplasia.
Pharmacology Alfuzosin is a quinazoline-derivative alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, alfuzosin is a selective inhibitor of the alpha(1) subtype of alpha adrenergic receptors. In the human prostate, alfuzosin antagonizes phenylephrine (alpha(1) agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1a adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that alfuzosin competitively antagonized the pressor effects of phenylephrine (an alpha(1) agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of alfuzosin results from a decrease in systemic vascular resistance and the parent compound alfuzosin is primarily responsible for the antihypertensive activity.
Toxicity Side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.
Affected Organisms
Humans and other mammals
Biotransformation Hepatic. Alfuzosin undergoes extensive metabolism by the liver, with only 11% of the administered dose excreted unchanged in the urine. Alfuzosin is metabolized by three metabolic pathways: oxidation, O-demethylations, and N-dealkylation. The metabolites are not pharmacologically active. CYP3A4 is the principal hepatic enzyme isoform involved in its metabolism.
Absorption Absorption is 50% lower under fasting conditions
Half Life 10 hours
Protein Binding 82%-90%
Elimination Following oral administration of 14C-labeled alfuzosin solution, the recovery of radioactivity after 7 days (expressed as a percentage of the administered dose) was 69% in feces and 24% in urine.
Distribution * 3.2 L/kg [healthy male middle-aged volunteers]
References
McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. [Pubmed]
Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. [Pubmed]
Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. [Pubmed]
Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. [Pubmed]
Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

参考文献

供应商提供 Google Scholar IconGoogle Scholar PubMed iconPubMed Google Books IconGoogle Books
  • McKeage K, Plosker GL: Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53. Pubmed
  • Wilde MI, Fitton A, McTavish D: Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs. 1993 Mar;45(3):410-29. Pubmed
  • Andersson KE, Lepor H, Wyllie MG: Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate. 1997 Feb 15;30(3):202-15. Pubmed
  • Elhilali MM: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583-96. Pubmed
  • Roehrborn CG: Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker. Urology. 2001 Dec;58(6 Suppl 1):55-63; discussion 63-4. Pubmed
  • U.S. Pat., 1982, Synthelabo, 4 315 007; CA, 96, 162737e, (synth)
  • Allen, J., J. Labelled Compd. Radiopharm., 1983, 20, 1283, (synth)
  • Scott, M.G. et al., Eur. J. Clin. Pharmacol., 1989, 37, 53, (pharmacokinet)
  • Rouchouse, A. et al., J. Chromatogr., 1990, 506, 601, (hplc, enantiomers)
  • Lefevre-Borg, F. et al., Br. J. Pharmacol., 1993, 109, 1282, (pharmacol)
  • Wilde, M.I. et al., Drugs, 1993, 45, 410, (rev)
  • Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 342
正在搜索,请耐心等待...(如果遇到网页错误或者长时间没有结果,请刷新页面[F5])

专利

专利

PubChem iconPubChem Patent Google Patent Search IconGoogle Patent

互联网资源

互联网资源

百度图标百度 google iconGoogle